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Objective: Premature senescence of lymphocytes is a hallmark of inflammatory rheu-
matic diseases such as rheumatoid arthritis (RA). Early T-cell aging affects conventional 
T-cells but is presumably not limited to this cell population; rather it might also occur 
in the regulatory T-cells (Tregs) compartment. In RA, Tregs fail to halt aberrant immune 
reactions and disease progression. Whether this is associated with early Treg senes-
cence leading to phenotypic and functional changes of this subset is elusive so far.
Methods: Eighty-four RA patients and 75 healthy controls were prospectively enrolled 
into the study. Flow cytometry, magnetic-associated cell sorting, and cell culture exper-
iments were performed for phenotypic and functional analyses of Treg subsets. T-cell 
receptor excision circle (TREC) levels and telomere lengths were determined using 
RT-PCR.
results: In this paper, we describe the novel CD4+FoxP3+CD28− T-cell subset (CD28− 
Treg-like cells) in RA patients revealing features of both Tregs and senescent T-cells: Treg 
surface/intracellular markers such as CD25, CTLA-4, and PD-1 as well as FOXP3 were 
all expressed by CD28− Treg-like cells, and they yielded signs of premature senescence 
including reduced TREC levels and an accumulation of γH2AX. CD28− Treg-like could 
be generated in vitro by stimulation of (CD28+) Tregs with TNF-α. CD28− Treg-like cells 
insufficiently suppressed the proliferation of effector T-cells and yielded a pro-inflamma-
tory cytokine profile.
conclusion: In conclusion, we describe a novel T-cell subset with features of Tregs 
and senescent non-Tregs. These cells may be linked to an aberrant balance between 
regulatory and effector functions in RA.
Keywords: regulatory T cells, rheumatoid arthritis, immunosenescence, aging, premature, autoimmunity
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inTrODUcTiOn
Regulatory T-cells (Tregs) were identified as sentinels of the 
immune response keeping aberrant immune reactions in track 
and preventing autoimmunity. The current understanding 
of the pathogenesis of rheumatoid arthritis (RA) is that this 
equilibrium is disturbed, in part due to quantitative and/or 
qualitative defects of Tregs [reviewed in Ref. (1)]. Currently 
available data on this topic, however, are contradictory in part: 
Lawson et  al., for example, observed a reduced prevalence of 
circulating CD4+CD25high Tregs in patients with early active RA 
(2), whereas others were unable to reproduce this finding (3, 4). 
Ehrenstein et al. reported a defect of Tregs in the suppression 
of pro-inflammatory cytokine production (5), and Nie et  al. 
showed a reduced suppression of proliferating effector cells 
by Tregs that was TNF dependent (6). Other groups, however, 
reported that the suppressive function of Tregs in RA is normal 
(3, 4, 7).
These discrepancies are potentially linked to the fact that 
Tregs are not a single cell population but rather comprise devel-
opmentally and functionally distinct subsets that may vary 
among RA populations. Similar to non-Tregs are educated in the 
thymus and are then released in a “naïve-like” CD25+CD45RA+ 
phenotype into periphery (8, 9). Upon antigen contact, Tregs 
differentiate into a “memory-like” CD25hiCD45RO+ phenotype 
(10). Memory-like Tregs have a lower proliferative capacity 
and different homing behavior compared to naive-like Tregs 
and yield shorter telomeres as well as a lower content of T-cell 
receptor excision circles, an extrachromosomal DNA byprod-
ucts of T-cell receptor (TCR) rearrangement that is diluted 
by peripheral T-cell division, indicating a longer replicative 
history.
During aging, the thymus undergoes progressive involu-
tion leading to an elevated homeostatic pressure on peripheral 
T-cells (11, 12). Proliferation of peripheral T-cells compensates 
for dwindling thymic output until telomeres are contracted to 
levels known as the “Hayflick limit.” At this stage, non-Tregs 
undergo senescence-associated phenotypical and functional 
changes such as downregulation of CD28. Due to the fact that 
Tregs display even shorter telomeres than non-Tregs, it is con-
ceivable that Tregs proliferating in periphery reach the “Hayflick 
limit” even earlier (13). Impaired Treg homeostasis and function 
might then result in an increased risk of immune-mediated 
disorders.
In RA, senescence of non-Treg including the accumulation of 
CD28−CD4+ T-cells has been observed even in young individuals 
(14, 15). CD28− T-cells from RA patients are pro-inflammatory 
and cytotoxic, and a high prevalence of this cellular subset has 
been associated with higher disease severity and cardiovascular 
events (14, 16–18). Whether in RA, premature senescence includ-
ing the loss of CD28 molecule also affects Tregs has not been 
investigated so far. From a mouse model with a conditional CD28 
knockout in Tregs we know that the loss of this co-stimulatory 
molecule severely compromises Treg function leading to the 
development of autoimmunity (19).
This study aims at the identification and characterization of 
CD4+CD28−FoxP3+ T-cells in patients with RA.
PaTienTs anD MeThODs
study Population
This was a prospective study of consecutive patients with a final 
diagnosis of RA based on the 2010 ACR/EULAR criteria (20) as 
well as age- and sex-matched healthy individuals (HC). Detailed 
medical history including disease duration, prior, and current 
treatments was obtained from each patient. Each patient also 
underwent full clinical assessment with determination of disease 
activity according to the simplified disease activity index (SDAI) 
(21) and the disease activity score 28 (22). Whenever available, 
synovial fluid samples were obtained from patients undergoing 
routine joint aspiration.
Peripheral Blood Mononuclear cells 
(PBMcs) and cell culture
Peripheral venous blood or synovial fluid was drawn from each 
individual, and PBMCs were isolated by Histopaque density 
gradient centrifugation. The total cell number was determined 
by a Beckmann Coulter. Cells were cultured at 1 × 106 cells/ml in 
RPMI 1640 containing 10% fetal calf serum, 2 mM l-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin in the presence 
of 20 U/ml human recombinant IL-2 (SIGMA, Vienna, Austria) 
and initial stimulation with 10 μg/ml plate-bound anti-CD3 Ab.
Flow cytometry
Surface and intracellular staining of freshly isolated PBMCs 
was performed using appropriate combinations of antibod-
ies for detection of CD3, CD4, CD28, CD25, CD127, FoxP3, 
CTLA-4, IL-10, TNF-α, Th1-type cytokines IL-2 and IFN-γ, 
Th2-type cytokine IL-4 and Th17-type cytokine IL-17 (all Becton 
Dickinson, San Diego, CA, USA), and γH2AX (Cell Signaling, 
Danvers, MA, USA). Surface staining for 20 min was followed by 
permeabilization for 30 min and intracellular staining for 30 min 
according to a routine protocol. Golgi transport was inhibited 
by brefeldin A (10 ng/ml) or monensin (10 ng/ml) 4 h prior to 
cytokine staining. Appropriate isotype controls were used. Stained 
cells were analyzed on a FACS Canto II (Becton Dickinson). Data 
are analyzed with DIVA software and FlowJo.
isolation of T-cell subsets
For functional assays, CD4+ T-cells were isolated by positive 
selection of PBMCs labeled with magnetic-bead conjugated anti-
human CD4 mAbs using MACS MultiSort Kit and autoMACSPro 
according to manufacturer’s instructions (Miltenyi). Purified 
CD4+ T-cells were then separated into the CD28+CD25+CD127dim 
(conventional regulatory), CD28+CD25− (conventional non-
regulatory), and CD28−CD25+CD127dim (senescent Treg-like) 
fractions by another sorting step using FACS technology (FACS 
Aria). In order to obtain sufficient numbers of RA Tregs, pre-
enrichment of PBMCs was necessary and resulted in upregulation 
of CD25. Therefore, isolation of Treg subsets was based on CD25 
positivity as well as absence of CD127. For CD28 downregulation 
experiments, Tregs were isolated using CD4+CD25+CD127dim/− 
Reg. T Cell isolation Kit II (Miltenyi) and autoMACSPro. For 
validation, flow cytometry was then performed to determine 
purity (>90%) of selected cells.
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Determination of Tcr Diversity
RNA from enriched subsets was extracted using RNeasy Protect 
Mini Kit (Qiagen, Germantown, MD, USA) according to the man-
ufacturer instructions. RNA was used for reverse transcription 
with First Strand cDNA Synthesis Kit for RT-PCR AMV (Roche) 
according to the manufacturer regulations. cDNA was diluted 
1:5 for PCR using AmpliTaq Gold™ DNA Polymerase (Applied 
Biosystems), 1× PCR Gold Buffer (Applied Biosystems), 2.5mM 
MgCl2 (Applied Biosystems), 0.4  mM dNTP Polymerization 
Mix (GE Healthcare), 0.5 μM TCR C β 5′FAM labeled primer 
(Ingenetix, Vienna, Austria), and 0.5  μM unlabeled TCR V β 
primers (Ingenetix) according to Hingorani et  al. (23). Primer 
sequences are listed in Table S2 in Supplementary Material. Cycle 
conditions were a denaturation step at 94°C for 6 min, 35 cycles of 
94°C for 1 min, 59°C for 1 min, and 72°C for 1 min, a final anneal-
ing step at 72°C for 7 min. After amplification, the PCR product 
was supplemented with GeneSCan™-500 TAMRA™ Size 
Standard (Applied Biosystems) and HI-DI Formamide (Applied 
Biosystems). Electrophoresis was performed with ABI Prism 310 
Genetic Analyzer (Applied Biosystems), and 310 Data Collection 
Software. Analysis was done by GeneScan® Software (Applied 
Biosystems). Calculations included peak count (Complexity 
score) and single peak area in percent of whole peak area.
Senescence-Associated β-Galactosidase Assay
Freshly isolated PBMCs were treated with the “Quantitative 
Cellular Senescence Assay Kit” (Cell Biolabs) according to the 
manufacturer’s instructions. Afterward, a surface and intracel-
lular staining of cells was performed as described above.
Determination of Telomere length
DNA from enriched subsets was extracted using QIAamp DNA 
Blood Mini Kit (Qiagen, Germantown, MD, USA) accord-
ing to the manufacturer instructions. Telomere lengths were 
measured using DNA from PBMCs as well as T-cell subsets by 
quantitative real-time PCR analysis and LightCycler FastStart 
DNA Master SYBR Green I (Roche, Vienna, Austria) as previ-
ously described (24).
suppression assay
CD4+ T-cells were isolated always from the same healthy donor 
(JF) since RA effector cells were reported to be resistant to Treg-
mediated suppression (5). Cells were incubated with CellTrace 
Violet (Life Technologies) and cultured in the presence or 
absence of CD28+CD25+CD127dim or CD28−CD25+CD127dim RA 
T-cells at a 1:1 ratio. Autologous CD28+CD25+CD127dim served as 
a control. Cells were stimulated by adding 10 μg/ml anti-CD3 Ab 
and incubated at 37°C for 3 days and analyzed by flow cytometry. 
To elucidate the impact of TNF-α and IFN-γ on the suppressive 
potential of different subsets, we added neutralizing antibodies 
(R&D systems) at 10 μg/ml. A normal goat IgG control was also 
added at the start of culture accounting for any non-specific 
changes.
Proliferation Assay
For all experiments, freshly purified PBMCs were resuspended in 
PBS at 5–10 × 106 cells/ml and incubated with CFSE (1 μM) for 
7 min at 37°C. Cells were washed three times and resuspended 
in culture medium. Cells were stimulated with plate-bound 
anti-CD3 (10 μg/ml, 18 h) or PHA (1 μg/ml) and cultured for 
72 h. Afterward cells were stained as described in Section “Flow 
Cytometry.”
apoptosis assay
Freshly isolated PBMCs were stimulated with plate-bound 
anti-CD3 (10 μg/ml) or PHA (1 μg/ml) and cultured for 18 h. 
Afterward cells were harvested and stained for Annexin V and 
viability dye (ebioscience, San Diego, CA, USA) as well as surface 
markers according to the manufacturer’s protocol. Annexin 
V+ cells represent apoptotic cells, viability dye+ cells represent 
necrotic cells, and double positive cells represent late apoptotic 
cells.
CD28 Downregulation Experiments
CD4+CD25+CD127dim/− Tregs were isolated using AutoMACS 
(Miltenyi, Bergisch Gladbach, Germany) according to the 
manufacturer’s instructions. Subsequently, cells were cultured 
as described (25): in brief, 1 ×  105 cells/ml were cultured in a 
96-well plate with culture media and anti-CD3/CD28 MoAb-
coated microbeads (Life Sciences, Waltham, MA, USA) at a 4:1 
bead-to-cell ratio and were stimulated with 200 U/ml IL-2, with 
or without 100 ng/ml TNF-α (SIGMA) or IL-15 (Life Sciences). 
After 6 days of cultivation, the cells were harvested, washed, and 
then cultured in the presence of 20 U/ml IL-2 for two more days. 
Thereafter, the expanded Tregs were restimulated for another 
6 days with anti-CD3/CD28 MoAb-coated microbeads at a bead-
to-cell ratio of 2:1 and 200 U/ml IL-2. Cells were analyzed after 
each expansion phase.
statistical analysis
All statistical analyses were performed using the SPSS program, 
version 23 (Chicago, IL, USA). In case of a normal distribution 
(tested with the Kolmogorov–Smirnov test) of the continuous 
variables, the mean and SD are shown, and we used the two-sided 
Student’s t-test (comparison of two groups) or ANOVA (compari-
son of three or more groups) for comparisons. In case of a non-
parametric distribution, the median and range are shown, and we 
used the Mann–Whitney U and the Kruskal–Wallis tests to assess 
differences between groups. Correlation between variables was 
evaluated by the Spearman’s rank correlation coefficient. Paired 
data were compared with the Wilcoxon test.
study approval
This study was approved by the Institutional Review Board of 
the Medical University Graz, and written informed consent was 
obtained from each individual prior to inclusion in the study.
resUlTs
cD4+cD28−FoxP3+ T-cells have a Treg-
like Phenotype and are Prevalent in ra
We know that in RA, (1) a proportion of T-cells lack the co-
stimulatory molecule CD28, (2) the loss of CD28 reflects early 
FigUre 1 | cD28− regulatory T-cells (Tregs)-like cells are enriched in patients with rheumatoid arthritis (ra). Graphs show (a) representative dot plots of 
CD28− Treg-like cells (gated on CD4+FoxP3+ T-cells) of patients with RA (n = 84) and HC (n = 75) and statistical analysis as well as (B) prevalences of CD28− Treg-
like cells and (c) CD28+ Tregs of healthy controls (HC, blue) and RA patients (red); Mann–Whitney U test and Student’s t-test, respectively, were used to assess 
differences between groups. *p ≤ 0.05.
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T-cell senescence and is partially caused by pro-inflammatory 
stimuli, and (3) Tregs undergo a similar development to non-
Tregs from a naïve-like to a memory-like status. We therefore 
investigated whether expression of CD28 is reduced on FoxP3+ 
T-cells (which is the most specific marker for Tregs) from RA 
patients.
In RA patients but not in controls, we observed a FoxP3+ 
T-cell subset lacking the expression of CD28. The prevalence 
of circulating CD4+CD28−FoxP3+ T-cells was higher in RA 
patients compared to healthy individuals [0.7% of total CD4+ 
(range 0–19.2) vs. 0.2% (0–17); p  =  0.029; Figures  1A,B], 
whereas the frequency of CD4+CD28+FoxP3+CD25+ Tregs was 
equal in both groups [5% of total CD4+ (3.2–7.3) vs. 4.9% (3.2–
9.5); p = 0.988; Figure 1C]. The intensity of FoxP3 expression 
was similar in CD28− and CD28+ subsets (MFI: 601.8 ± 200.4 
vs. 634.8 ±  196.5, p >  0.05, Figures  2A,B). In synovial fluid 
samples from RA patients, we noted that 3.8% (1.6–18.8) of 
CD4+FoxP3+ T-cells were negative for CD28 (n = 8, data not 
shown).
Alongside FoxP3, CD25 and a low expression of CD127 are 
characteristic for Tregs (26, 27). CD4+ CD28−FoxP3+ T-cells 
were positive for CD25 and expressed low levels of CD127; both 
markers, however, were reduced relative to CD4+CD28+FoxP3+ 
Tregs: CD25, MFI: 328 (199–2,068) vs. 1,998 (1,456–2,946); 
p  <  0.001; Figure  2C and CD127, MFI: 454 (111–905) vs. 
1,206 (906–1,961); p <  0.001; Figure  2D. CTLA-4, PD-1, and 
CD15s are other typical markers of Tregs, all of them were 
found on CD4+CD28−FoxP3+: CTLA-4 expression was similar 
in CD4+CD28−FoxP3+ T-cells and CD4+CD28+FoxP3+ Tregs 
[MFI: 123.5 (103–350) vs. 122 (104–648); p = 0.499; Figure 2E], 
whereas PD-1 was higher [MFI: 449.5 (167–811) vs. 258.5 
(221–480); p = 0.017; Figure 2F] and CD15s lower [MFI: 864.5 
(647–914) vs. 1,102.5 (690–1,251); p = 0.028; Figure 2G] in the 
former compared to the latter cell population. CCR6, another 
molecule normally expressed by Tregs was almost absent on 
CD4+CD28−FoxP3+T-cells [0.2% (0–7.5) of CD4+CD28−FoxP3+ 
T-cells were positive for CCR6+ vs. 39.8% (28.9–55.2) of CD28+ 
Tregs; p = 0.012, Figure 2H] (28).
Collectively, these analyses suggest that CD4+CD28−FoxP3+ 
T-cells have a Treg-like phenotype.
cD28− Treg-like cells Underwent cellular 
senescence
To investigate whether the novel CD28− Treg-like subset 
revealed signs of cellular senescence in addition to the loss of 
CD28, we undertook the following experiments: first, we tested 
the accumulation of γH2AX foci, which represent repair-proof 
double-strand breaks in DNA (29). Second, we performed TCR 
spectratyping because TCR diversity is known to diminish along 
with T-cell aging (30). Third, we tested the accumulation of 
senescence-associated β-galactosidase (SABG) another known 
biomarker of cellular senescence (31). Fourth, we measured the 
telomere length given that a shrinkage of telomeres is considered 
to indicate replicative senescence (32).
FigUre 2 | surface markers of cD28− regulatory T-cells (Tregs)-like cells and cD28+ Tregs. (a) Gating strategy for the identification of CD28− Treg-like cells 
(gated on CD4+ cells). (B–h) Graphs show representative histograms or dot plots and box plots of 10 rheumatoid arthritis patients of (B) FoxP3, (c) CD25, (D) 
CD127, (e) CTLA-4, (F) PD-1, (g) CD15s, and (h) CCR6 expression of CD28+ Tregs (green), CD28− Treg-like cells (blue), and conventional (FoxP3−) T-cells (black 
solid line). Isotype control expression levels are indicated by dashed lines. Mann–Whitney U test was used to assess differences between groups. *p < 0.05.
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As depicted in Figure  3A, CD28− Treg-like cells showed 
higher γH2AX mean fluorescence intensity than CD28+ Tregs 
[MFI: 6,422 (2,952–258,589) vs. 4,875 (2,875–7,743), p = 0.046]. 
Similarly, TCR diversity was reduced in CD28− Treg-like cells [84 
(36–104)] compared to their CD28+ counterparts [115 (109–125); 
p = 0.037; Figure 3B]. SABG expression, moreover, was likewise 
enhanced in CD28− Treg-like cells [MFI: 1,117 (671–1,263) vs. 
499 (474–591); p = 0.043; Figure 3C].
Interestingly, telomere length was similar in CD28− Treg-like 
cells [6.11  kbp (5.46–6.19)] and CD28+ Tregs [5.89 (5.6–6.17), 
p = 0.373, Figure 3D]. From previous studies we know, however, 
that the telomere length of Tregs is reduced already (compared to 
non-Tregs), and a further shrinkage of telomeres is thus unlikely 
to occur (13).
association of cD28− Treg-like cells with 
clinical Parameters of ra
Clinical characteristics of RA patients and controls are depicted 
in Table S1 in Supplementary Material. Two (3.3%), 8 (13.1), and 
32 (52.5) out of the 61 RA patients with available SDAI values 
had high, moderate, or low disease activity, respectively; 19 (31.1) 
patients were in clinical remission (33). Five (6%) RA patients 
had early disease (≤2 years’ duration).
Frequencies of CD28− Treg-like cells (but not those of 
CD28+ Tregs) correlated with age in RA patients and controls 
(corrcoeff  =  0.416, p  <  0.001 and corrcoeff  =  0.557, p  <  0.001, 
respectively; Figure S1A in Supplementary Material). Neither the 
prevalence of CD28− Treg-like cells nor those of CD28+ Tregs 
was linked with disease duration, acute phase reactants, clinical 
FigUre 3 | cD28− regulatory T-cells (Tregs)-like cells show evidence of advanced replicative senescence. Graphs show (a) expression of γH2AX, (B) 
T-cell receptor diversity, (c) expression of senescence-associated β-galactosidase (SABG), and (D) telomere lengths of CD28+ Tregs (green), CD28− Treg-like cells 
(blue), and naive CD45RA+ T-cells (gray). Mann–Whitney U test was used to assess differences between groups. *p < 0.05; n = 5.
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variables, or treatment (Figures S1B,C in Supplementary Material 
and data not shown).
cD28− Treg-like cells can Be generated 
In Vitro
Previous studies reported that the downregulation of CD28 on 
T-cells is driven by pro-inflammatory signals including TNF-α 
or IL-15, which are also highly expressed in RA patients (34, 35). 
To test if these agents mediate the generation of CD28− Treg-like 
cells in  vitro, we isolated CD4+CD25highCD127dim/− Tregs from 
healthy individuals and cultured them in the presence or absence 
of IL-15 or TNF-α. We observed a significant decrease of CD28 
on Tregs stimulated with TNF-α [3,295 (1,293–16,853)] com-
pared to mock stimulation [5,628.5 (1,782–16,559); p =  0.025, 
Figure  4A]. A decrease of CD28 was also observed following 
incubation with IL-15. This difference, however, did not reach 
statistical significance [4,483 (713–15,309); p = 0.138]. Moreover, 
the reduced expression of CD28 was robust following elongated 
stimulation with TNF-α but not IL-15 (Figure 4B). Expression of 
CD25, CD127, and FoxP3 was not different following either way 
of stimulation and remained in Treg-specific expression levels 
(Figure 4C).
cD28− Treg-like cells Produce high 
levels of Pro- and anti-inflammatory 
cytokines
Next, we examined the cytokine profile of CD28− Treg-like cells 
from RA patients. CD28+ Tregs are known to produce high levels 
of IL-10, which is one way how they inhibit effector cells (36). 
CD28− non-Tregs acquire a senescence-associated secretory 
phenotype, which is characterized by the predominate release of 
Th1 cytokines such as TNF-α and IFN-γ (37).
CD28− Treg-like cells yielded a more pronounced production 
of IL-10 than CD28+ Tregs following stimulation with anti-CD3 
[4% (1.5–13.1) of CD28− Treg-like cells vs. 0.55% (0.3–1.6) of 
CD28+ Tregs were positive for IL-10; p =  0.005, Table  1]. At 
TaBle 1 | cytokine production of cD28+ regulatory T-cells (Tregs) as well as cD28− Treg-like cells following stimulation in vitro.
% of cD28− Treg-like cells % of cD28+ Tregs p-Valuea % of conv.cD28− T-cells p-Valueb
IL-2 15.45 (5.1–31.1) 4.55 (1.1–12) 0.005 8.8 (3.6–35.6) 0.114
IL-4 4.3 (1.2–7.9) 0.3 (0.1–0.8) 0.005 3.75 (1.3–11.5) 0.005
IL-10 4 (1.5–13.1) 0.55 (0.3–1.6) 0.005 4.15 (0.5–13.4) 0.594
IL-17 4.9 (1.5–14.6) 0.7 (0.2–1.7) 0.005 4.05 (1.6–9.7) 0.203
TNF-α 18 (5.7–34.9) 11.5 (4.8–18.3) 0.005 13.6 (3.4–37) 0.074
IFN-γ 16.6 (4.3–40.4) 6.8 (2.4–16.1) 0.005 10.05 (2.8–36.4) 0.022
aCD28− Treg-like cells vs. CD28+ Tregs.
bCD28− Treg-like cells vs. conv.CD28− T-cells.
FigUre 4 | In vitro downregulation of cD28 in regulatory T-cells (Tregs) in the presence of TnF-α. Graphs show (a) representative histograms showing 
CD28 expression of control Tregs (gray), following IL-15 stimulation (orange), and following TNF-α stimulation (violet), and box plots show median expression of 
CD28 (MFI) in Tregs of eight healthy individuals after the first expansion phase, (B) the second expansion phase, respectively; and (c) representative histograms of 
CD25, CD127, and FoxP3 expression. Mann–Whitney U test was used to assess differences between groups. *p < 0.05.
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the same time, however, cytokines characteristic for Th1 (IL-2, 
TNF-α, and IFN-γ), Th2 (IL-4), and Th17 lineages (IL-17) were 
also more frequently produced by CD28− Treg-like cells com-
pared to CD28+ Tregs (all p = 0.005). The largest difference was 
observed concerning the production of IL-4 (14-fold).
Conventional senescent CD4+ T-cells produced lower 
amounts of IL-4 and IFN-γ than CD28− Treg-like cells, however, 
no difference was found regarding the production of IL-10. For 
details see Table 1.
cD28− Treg-like cells are less 
suppressive than cD28+ Tregs
The suppression of effector T-cells is a defining feature of 
regulatory cells. Tregs from mice with a conditional knockout 
for CD28 are non-suppressive, and in RA patients, Treg func-
tion has been reported (at least by some authors) to be defective 
(5, 19). Therefore, we studied the ability of CD28− Treg-like 
cells to suppress the proliferation of non-Tregs. As depicted in 
Figure  5A, the suppressive function of CD28− Treg-like cells 
from RA patients was compromised compared to that of CD28+ 
Tregs [median reduction of proliferation of stimulated non-Tregs: 
−2.2% (−8.7.1 to 77.7) vs. 32.7% (−0.4 to 77.9); p = 0.008].
Given that TNF-α and IFN-γ were shown to interfere with 
Treg function in vitro and that CD28− Treg-like cells produced 
high levels of these cytokines (38, 39), we tested whether the 
suppressive capacity of CD28− Treg-like cells was restored by 
the blockade of TNF-α or IFN-γ. The addition of neutralizing 
antibodies had no effect on the suppressive function of CD28− 
Treg-like cells or CD28+ Tregs (Figures 5B,C).
cD28− Treg-like cells are Prone to 
apoptosis
Regulatory T-cells from CD28− deficient mice have a pro-
nounced proliferative/survival disadvantage (19). Therefore, 
FigUre 5 | cD28− regulatory T-cells (Tregs)-like cells show reduced suppressive capacity. Graphs show (a) representative histograms and box plots of 
in vitro suppression assays with CD28+ Tregs (green), CD28− Treg-like cells (blue), as well as conventional T-cells (gray) of nine rheumatoid arthritis patients, (B) box 
plots of in vitro suppression assays with CD28+ Tregs (green) as well as (c) CD28− Treg-like cells (blue) in the presence of neutralizing ab to IFN-γ (yellow) or TNF-α 
(pink); (D) proliferative potential of CD28+ Tregs (green) and CD28− Treg-like cells (blue) following stimulation with anti-CD3; and (e) apoptotic (green), late apoptotic 
(blue), as well as necrotic (red) cells. Mann–Whitney U test was used to assess differences between groups. *p < 0.05.
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we analyzed the proliferative capacity and apoptosis induction 
of CD28− Treg-like cells. Upon stimulation with anti-CD3, we 
observed a lower rate of cell division of CD28− Treg-like cells 
compared to CD28+ Tregs [53.1% CFSEhigh (range 14.5–93.6) vs. 
5.4% (0.9–30.6), respectively; p = 0.008; Figure 5D]. In addition, 
we performed Annexin V staining assays in order to analyze 
apoptosis induction this subset. In the CD28− Treg-like subset, 
increased frequencies of early apoptotic [7% (range 2–25.7) 
vs. 1% (0.5–2.5); p =  0.005], necrotic [1.9% (0–9.2) vs. 0.2% 
(0.1–0.6); p = 0.011], and late apoptotic cells [17.1% (7.5–51.7) 
vs. 2.6% (1.3–8.4); p = 0.005] were observed upon stimulation 
with anti-CD3 compared to the CD28+ Treg population. Overall, 
more than 30% of CD28− Treg-like cells were apoptotic or 
necrotic upon activation compared to only 5% of CD28+ Tregs 
(Figure 5E).
DiscUssiOn
In the present study, we describe the novel CD4+ CD28−FoxP3+ 
T-cell subset. These cells reveal a phenotype compatible with 
senescent Tregs, have a reduced suppressive capacity compared 
to conventional CD4+ CD28+ FoxP3+ Tregs, show an increased 
production of pro- and anti-inflammatory cytokines, and display 
a high apoptosis rate. CD28− Treg-like cells can be generated 
in vitro upon stimulation with TNF-α in vitro, and they are found in 
RA patients in peripheral blood and at sites of inflammation 
in vivo.
The increment of CD4+CD28−FoxP3+ T-cells in RA patients 
compared to HC was modest, albeit some individuals showed 
remarkable frequencies of this cell subset (with a maximum of 
19.2% of all CD4+ T-cells). Given that Treg frequencies account 
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for only ~5% of the total CD4+ T-cell population, even small 
changes in the composition of this subset might lead to major 
changes in the immune response, particularly in cases where 
the immune system is disturbed already, such as in RA. CD28− 
Treg-like cells only weakly suppressed effector T-cells in vitro and 
released pro- as well as anti-inflammatory cytokines. Given that 
the ability to suppress effector cells is the most robust definition 
of Treg function, the question arises, whether CD28− Treg-like 
cells still can be deemed as a regulatory subset. A major argu-
ment in favor of their regulatory origin is the expression of the 
transcription factor FoxP3. FoxP3 is essential for Treg develop-
ment and function (27), and previous studies demonstrated 
that ectopic expression of FoxP3 in effector T-cells by retroviral 
gene transfer is sufficient to induce a Treg-like phenotype and 
function (40, 41). Besides, CD28− Treg-like cells had strongly 
upregulated inhibitory surface molecules such as PD-1 and 
CTLA-4 and produced the immunosuppressive cytokine IL-10 
(even more than CD28+ Tregs).
The most plausible alternative interpretation of our findings 
is that CD4+CD28−FoxP3+ T-cells are senescent non-Tregs 
that have transiently upregulated FoxP3 upon stimulation. 
CD4+CD28−FoxP3+ T-cells, however, were not only observed in 
RA patients with active disease but also in those in remission, 
and it is unlikely that CD4+CD28− T-cells are continuously 
stimulated in patients where all other disease activity param-
eters are low. In addition, transient FoxP3 expression has been 
reported for naïve T-cells only, whereas memory and effector 
T-cells (which CD28− T-cells belong to) seem not to upregulate 
this factor (42).
CD28− Treg-like cells described in the present study are 
similar to Tregs identified in a mouse model with a condi-
tional knock-out for CD28 (19). These animals suffer from 
severe autoimmunity due to defective Tregs, which are unable 
to suppress inflammation. Specifically, Tregs from the CD28 
knockout mouse model yielded a similar phenotype to human 
CD28− Treg-like cells such as the loss of CCR6 or the reduced 
expression of CD25, and an elevated production of IFN-γ. 
CCR6 is required for homing of Tregs to inflammatory sites 
(24), and Tregs of CD28− deficient mice were virtually absent in 
inflamed skin lesions (43). In the synovial fluid of RA patients, 
CD28− Treg-like cell levels were increased relative to circulation; 
however, this does not exclude a homing defect of CD28− Treg-
like cells because they could have been generated locally under 
the influence of pro-inflammatory cytokines such as TNF-α 
with subsequent efflux to periphery. Our in  vitro experiments 
demonstrated that TNF-α downregulates CD28 on Tregs and 
TNF-α levels are known to be high in inflamed joints of RA 
patients (44). Nevertheless, TNF-α-induced CD28− Tregs do 
not completely reflect CD28− Treg-like cells described in  vivo 
since expression levels of CD25 and CD127 were unaltered in 
in vitro stimulated cells. These differences are potentially caused 
by the length of stimulation and/or the presence of additional 
cytokines in  vivo.
CD28− Treg-like cells from RA patients had a clear survival 
disadvantage compared to CD28+ Tregs, which is again in line 
with the observations from the CD28 conditional knockout 
model (19). CD28− Treg-like cells yielding a lower proliferative 
capacity plus a higher apoptosis rate are presumably functionally 
unable to halt autoimmune effector cells. Besides, CD28− Treg-
like cells from RA patients released several pro-inflammatory 
cytokines such as IFN-γ or TNF-α which might further promote 
the inflammatory process (38). Previous studies reported that 
treatment of RA patients with TNFα blockers restores Treg 
function (5, 45), whereas in our group, no association of anti-
TNF therapy (or any other clinical variable except for age) with 
CD28− Treg-like cell prevalence or function was found. This 
might be explained by the clinical heterogeneity of our cohort 
and the small sample size that lacked the power to elucidate 
the relation between different clinical phenotypes, therapies and 
CD28− Treg-like cells. Larger studies are certainly needed to 
clarify this issue.
CD28− Treg-like cells from RA patients expressed lower 
levels of CD25 compared to Tregs, which might have had an 
impact on their regulatory function. CD25 has been reported 
to operationally differentiate naturally present, autoimmune-
preventive Tregs from other T-cells and therefore mediate 
immunosuppression (27). On the other hand, functional Treg 
subsets with a lower expression of CD25 have been reported, 
as well: a proportion of Tregs from aged mice, for example, 
showed decreased expression of CD25 (46, 47). These CD25low 
Tregs occurred predominantly in the spleen (48) but had 
comparable functional properties to CD25+ Tregs. Similarly, a 
CD4+CD25lowFoxP3+ Treg population has been observed in SLE 
patients, and given that SLE patients have a prematurely aged 
immune system with accumulation of CD28− T-cells (49), it 
is conceivable that (at least part of) this CD4+ CD25lowFoxP3+ 
Treg population was CD28−. A more recent study reported 
enhanced frequencies of CD25-FoxP3+ T-cells in RA patients 
and a negative correlation of this subset with disease activity 
(50). Unfortunately, no functional experiments were conducted 
with these cells thus not allowing to elucidate the overlaps and 
differences between these cell populations and clearly link CD4+ 
CD25lowFoxP3+ Tregs with CD28− Treg-like cells.
The most important limitation of this study is the uncertain 
identification of human Tregs by flow cytometry. No combina-
tion of surface molecules enables specific identification and 
isolation of Tregs. The transcription factors FoxP3 is still deemed 
as the most specific Treg marker; however, activated naive T-cells 
without suppressive function may transiently express this factor, 
as well. Second, RA is a heterogeneous disease with various 
clinical phenotypes. It is likely that the pathophysiology differs 
between various clinical subsets, and ideally, experiments would 
have been performed in different groups, stratified by their 
clinical phenotype. Third, we were unable to clarify whether 
CD28− Treg-like cells occur before the clinical onset of RA (thus 
presumably contributing directly to the pathogenesis of the dis-
ease) or whether they occur later in course, secondary to chronic 
inflammation. Previous studies investigating healthy individuals 
with a genetic risk for RA concluded that early T-cell senescence, 
which might also involve the Treg lineage, is in part genetically 
determined and might well occur before the clinical onset of 
disease (51).
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In conclusion, we describe a novel T-cell subset combin-
ing a regulatory phenotype with signs of T-cell senescence. 
This novel subset might represent a late developmental stage 
of Tregs (CD4+CD28−FoxP3+ T-cell). CD28− Treg-like cells 
revealed a reduced suppression of effector cells, produced 
pro- and anti-inflammatory cytokines, and had a survival 
disadvantage compared to CD28+ Tregs. The CD28− Treg-
like cell population might thus contribute to the pathogenic 
immune response in RA.
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